- The purpose of the guidelines national committee ccAFU was to propose updated french guidelines for prostate cancer.
- A Medline search was achieved between 2018 and 2020, as regards diagnosis, options of treatment and follow-up of prostate cancer (PCA), and to evaluate the different references specifying their levels of evidence.
- The guidelines outline the genetics, epidemiology and diagnosis of prostate cancer, as well as the concepts of screening and early detection. MRI, the gold standard imaging test for localized cancer, is indicated before prostate biopsies are performed. The therapeutic methods are detailed and indicated according to the clinical situation. Active surveillance is a reference therapeutic option for low-risk tumours with a low evolutionary risk. Early salvage radiotherapy is indicated in case of biological recurrence after radical prostatectomy. Androgen deprivation therapy (ADT) remains the backbone therapy in the metastatic stage. Docetaxel in combination with ADT improves overall first-line survival in synchronous metastatic prostate cancer. In this situation, the combination of ADT with abiraterone is also a standard of care regardless of tumor volume. Recent data indicate that ADT should be indicated with a new generation of hormone therapy (Apalutamide or Enzalutamide) in metastatic synchronous or metachronous patients, regardless of tumour volume. Local treatment of prostate cancer with radiotherapy improves survival in synchronous oligometastatic patients. Targeted treatment of metastases is being evaluated. In patients with castration-resistant prostate cancer (CRPC), new therapies that have emerged in recent years help to better control tumor progression and improve survival.
- These updated french guidelines will contribute to increase the level of urological care for the diagnosis and treatment for prostate cancer.
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie. 2020 Nov [Epub]
F Rozet, P Mongiat-Artus, C Hennequin, J B Beauval, P Beuzeboc, L Cormier, G Fromont-Hankard, R Mathieu, G Ploussard, R Renard-Penna, I Brenot-Rossi, F Bruyere, A Cochet, G Crehange, O Cussenot, T Lebret, X Rebillard, M Soulié, L Brureau, A Méjean
Comité de cancérologie de l'Association française d'urologie, groupe prostate, Maison de l'urologie, 11 rue Viète 75017 Paris, France; Institut mutualiste Montsouris, 42 boulevard Jourdan, 75014 Paris, France. Electronic address: ., Comité de cancérologie de l'Association française d'urologie, groupe prostate, Maison de l'urologie, 11 rue Viète 75017 Paris, France.